Skip to main content
. Author manuscript; available in PMC: 2014 Aug 18.
Published in final edited form as: Pharm Res. 2013 Feb 21;30(12):3254–3270. doi: 10.1007/s11095-013-1000-0

Table III.

Oral Bioavailability (% of Dose), % of the Drug Dose Transported in Lymph Over 8 h and Proportion of the Bioavailable Fraction Transported via the Lymph (as a %) Following Oral or Intestinal Administration of 1.6 mg/kg Halofantrine and 18.1 mg/kg Long Chain Lipid to Male Dogs, Rats and Mice. Data represent mean ± SEM for n=3–5 animals

Mice Rats Dogs
Bioavailability (%) 15.5±3.6a 28.5±0.2b 56.8 ± 7.3c
Lymphatic transport (%)d 2.0 ±0.5 6.9 ±0.3b 28.0±3.9c
Proportion transported via lymph (%) 12.9 24.2 49
a

Co-efficient of variation shown for mouse bioavailability data

b

Significantly greater than the same parameter in mice (p<0.05)

c

Significantly greater than the same parameter in mice and rats (p<0.05)

d

Studies were conducted in conscious animals administered halofantrine via the oral route, except for the lymphatic transport studies in mice and rats which were conducted in anaesthetised animals administered halofantrine via intraduodenal infusion. Lymphatic transport of halofantrine was similar in conscious and anaesthetised rats (Supplementary Material Fig. S1) providing support for the use of data in anaesthetised rats and mice in the current comparison.